KPSC sUTRAS

Alzheimer’s Treatment Access – Key Highlights • Only 20.8% of MCI/Alzheimer’s patients studied met potential eligibility criteria for lecanemab. • Advanced disease & late diagnosis were major barriers, accounting for ~40% of exclusions. • India faces a 24-month median gap between dementia onset and detection. • Limited access to amyloid PET and biomarker testing further restricts treatment eligibility. • Early diagnosis + better biomarker access are crucial to expand access to newer Alzheimer’s therapies.